Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Shareholder notification

26 Mar 2010 16:35

RNS Number : 2905J
China Real Estate Opportunities PLC
26 March 2010
 



China Real Estate Opportunities plc

 

Significant shareholder notification

 

In accordance with Rule 17 of the AIM Rules, China Real Estate Opportunities plc ("CREO" or the "Company") announces that on 26 March 2010 it was notified by a director and a significant shareholder of the following change in one of its significant shareholders.

 

On 22 March 2010, Treasury Holdings transferred its interests in Daylasin Limited to Richard Barrett, a director of the Company, and John Ronan, a significant shareholder in the Company. Mr Barrett and Mr. Ronan each hold 50 per cent of the shares in Treasury Holdings and, following this transaction, Daylasin Limited respectively.

 

Daylasin holds 5,345,819 ordinary shares of no par value in the Company, representing 11.13 per cent of the issued share capital of the Company. The price paid by Mr. Barrett and Mr. Ronan for their interests in Daylasin Limited equates to 348p for each share in the Company held by Daylasin Limited.

 

Following this transaction, Richard Barrett remains interested in 8,955,518 ordinary no par value shares representing 18.64 per cent of the issued share capital of the Company, John Ronan remains interested in 11,610,008 ordinary no par value shares representing 24.17 per cent of the issued share capital of the Company, and Treasury Holdings has no further interests in the Company.

 

Contact:

CREO

Ray Horney, Chairman

Tel: +44 (0) 1273 775 225

 

Sarah Moriarty, Investor Relations

Tel: + 353 1 618 9455

 

Matrix Corporate Capital LLP

Paul Fincham, Rob Naylor

Tel: +44 (0) 20 3206 7000

 

Davy

Des Carville

Tel: +353 1 679 6363

 

Citigate Dewe Rogerson Limited

Tom Baldock

Tel: +44 (0) 20 7638 9571

 

Murray Consultants

Ed Micheau

Tel: +353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSKKADNABKDNNB
Date   Source Headline
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension
17th Feb 202312:10 pmRNSLaunch of Open Offer and Posting of Circular
16th Feb 20236:04 pmRNSResult of Placing and Subscription
16th Feb 20239:05 amRNSSecond Price Monitoring Extn
16th Feb 20239:00 amRNSPrice Monitoring Extension
16th Feb 20237:00 amRNSPlacing and Subscription to raise a minimum £25m
15th Feb 202311:05 amRNSSecond Price Monitoring Extn
15th Feb 202311:00 amRNSPrice Monitoring Extension
30th Jan 20238:51 amRNSAward of Shares under Share Incentive Plan
23rd Jan 202311:47 amEQSCreo Medical (CREO): Progressing on all fronts
18th Jan 20232:05 pmRNSSecond Price Monitoring Extn
18th Jan 20232:00 pmRNSPrice Monitoring Extension
11th Jan 20237:00 amRNSFY 2022 Trading Update
16th Dec 20222:05 pmRNSSecond Price Monitoring Extn
16th Dec 20222:00 pmRNSPrice Monitoring Extension
1st Dec 20222:12 pmRNSHolding(s) in Company
24th Oct 20227:00 amRNSKamaptive Licence and Royalty Agreement with CMR
30th Sep 20227:00 amRNSTotal Voting Rights
23rd Sep 20227:00 amRNSExercise of Options
23rd Sep 20227:00 amRNSExercise of Options
22nd Sep 20227:00 amRNSChris Hancock elected as a Fellow of Royal Academy
9th Sep 20227:00 amRNSHalf-year Report
5th Sep 20227:00 amRNSNotice of Results
31st Aug 20227:00 amRNSTotal Voting Rights
8th Aug 20227:00 amRNSLTIP Awards and PDMR Dealing
4th Aug 20227:00 amRNSExercise of Options
3rd Aug 20227:00 amRNSH1 2022 Trading Update
2nd Aug 20227:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.